Gamma Delta T-cell Infusion for AML at High Risk of Relapse After Allo HCT

  • End date
    Dec 31, 2024
  • participants needed
  • sponsor
    H. Lee Moffitt Cancer Center and Research Institute
Updated on 10 May 2022
cell transplantation
minimal residual disease
residual tumor
blast cells


The purposes of the study are to determine the maximum tolerated dose (MTD) and effectiveness of Artificial Antigen Presenting Cell (AAPC)-expanded donor T-cells administered as a single infusion after an allogeneic hematopoietic cell transplant (alloHCT) to treat patients with Acute Myeloid Leukemia (AML).

Condition Acute Myeloid Leukemia
Treatment Gamma Delta T-Cell Infusion
Clinical Study IdentifierNCT05015426
SponsorH. Lee Moffitt Cancer Center and Research Institute
Last Modified on10 May 2022


Yes No Not Sure

Inclusion Criteria

Male or female, aged between 18 and 75 years of age undergoing allogeneic hematopoietic stem cell transplantation (alloHCT) or the treatment ELN 2017 adverse risk AML
Have < 5% blasts in bone marrow by morphology at the time of transplantation. Patients with pre-alloHCT or post-alloHCT flow cytometric or molecular evidence of MRD are allowed
Karnofsky performance status (KPS) ≥ 70% during the study screening
Free of symptomatic congestive heart failure or uncontrolled arrhythmia
Adequate organ function as defined per protocol
Negative serum pregnancy test
Note: Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for at least 30 days following study treatment (T-cell infusion); should a woman subject or female partner of a male subject become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately
Provision of signed and dated informed consent form
Stated willingness to comply with all study procedures and availability for the duration of the study
Agreement to adhere to Lifestyle Considerations throughout study duration

Exclusion Criteria

Current use of concomitant systemic glucocorticoid at the time of γδ T-cell infusion for any reason will not be allowed in order to avoid their immunosuppressive effects on γδ T-cell function
Active grade II-IV acute GVHD (patients with prior GVHD should be off prednisone for at least 14 days prior to infusion of the study cell product)
Uncontrolled serious infection
Morphologic relapse of leukemia at any timepoint after HCT
Active central nervous system malignancy
Pregnancy or lactation
Treatment with another investigational drug or other intervention within 14 days of T-cell infusion
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note